Exploring the New CHEST Bronchiectasis Guidelines

In "Exploring the New CHEST Bronchiectasis Guidelines," our experts turn to the first North American bronchiectasis guidelines and how they compare with international recommendations.

Dr. Basavaraj notes that he and Dr. Metersky were both authors on the newly released CHEST bronchiectasis guidelines and asks about their significance as the first North American guidelines for the disease. Dr. Metersky explains that meaningful differences exist between North American patients and those in other regions, including differences in which bacteria most commonly infect the airways, justifying geography-specific recommendations. He notes that most core concepts overlap substantially across international guidelines, since clinicians everywhere are largely addressing the same questions with similar answers, but the CHEST guidelines benefit from being the most recently published and therefore reflect the most current evidence.

Two elements stand out as distinctly new, according to Dr. Metersky: a recommendation supporting brensocatib, a newly available anti-inflammatory agent shown to reduce exacerbation risk, and a recommendation for tranexamic acid, an antifibrinolytic, in patients experiencing hemoptysis. Asked which recommendation holds the greatest potential to reshape care, Dr. Metersky points to anti-inflammatory therapy broadly, noting that inflammation has been established as a central driver of disease progression and that additional anti-inflammatory agents are currently in trials.

Dr. ElMaraachli compares the CHEST guidelines to the European Respiratory Society and British Thoracic Society guidelines, noting that all three continue to emphasize airway clearance and antibiotic treatment of exacerbations as core therapies. He highlights the CHEST guidelines' inclusion of DPP1 inhibition as a genuinely new element compared with earlier international guidance, alongside the tranexamic acid recommendation Dr. Metersky mentioned. On pseudomonas eradication, Dr. Basavaraj notes that limited supporting data led the CHEST panel to avoid recommending for or against eradication, individualizing the decision instead, a position that differs somewhat from other guidelines that more explicitly recommend eradication attempts.

The next episode in this series, "Managing Bronchiectasis: Acute Exacerbations vs Chronic Therapy," features Dr. Metersky separating chronic suppressive therapy from acute exacerbation management.